Creatine Safety, Tolerability, & Efficacy in Huntington's Disease
Carolyn Drazinic, MD, PhD, Medical Director of The University of Connecticut Health Center Huntington's Disease Program along with the Huntington Study Group (HSG), is conducting a clinical trial to study how creatine monohydrate effects people 18 years of age and older who have early signs of Huntington's Disease (HD). CREST-E is designed to look at if high doses of a pure-grade creatine monohydrate can slow down the decline that occurs in HD patients, by comparing it to a placebo (looks like study drug but has no active ingredient). CREST-E is designed to evaluate how safe creatine is and how the body will react to creatine. It will also look at how creatine affects the body.
Even though many people take creatine at lower doses, the high-doses being studied here have not been used before and so monitoring its safety at study visits is an important part of this study.
Over 60 research centers around the world will enroll up to 650 subjects for 37 months. This study is sponsored by the National Center for Complementary and Alternative Medicine (NCCAM) and the US Food and Drug Administration (FDA) Orphan Products division.
For more information visit www.clinicaltrials.gov/(NCT00712426) or call us at (860)679-4441.
Carolyn Drazinic, MD, PhD, MC6204
University of Connecticut Health Center
263 Farmington Avenue
Farmington, CT 06030-6204
Carolyn M. Drazinic, M.D., Ph.D.